Comparison of CSF markers and semi-quantitative amyloid PET in Alzheimer's disease diagnosis and in cognitive impairment prognosis using the ADNI-2 database
- PMID: 28441967
- PMCID: PMC5405503
- DOI: 10.1186/s13195-017-0260-z
Comparison of CSF markers and semi-quantitative amyloid PET in Alzheimer's disease diagnosis and in cognitive impairment prognosis using the ADNI-2 database
Abstract
Background: The relative performance of semi-quantitative amyloid positron emission tomography (PET) and cerebrospinal fluid (CSF) markers in diagnosing Alzheimer's disease (AD) and predicting the cognitive evolution of patients with mild cognitive impairment (MCI) is still debated.
Methods: Subjects from the Alzheimer's Disease Neuroimaging Initiative 2 with complete baseline cognitive assessment (Mini Mental State Examination, Clinical Dementia Rating [CDR] and Alzheimer's Disease Assessment Scale-Cognitive Subscale [ADAS-cog] scores), CSF collection (amyloid-β1-42 [Aβ], tau and phosphorylated tau) and 18F-florbetapir scans were included in our cross-sectional cohort. Among these, patients with MCI or substantial memory complaints constituted our longitudinal cohort and were followed for 30 ± 16 months. PET amyloid deposition was quantified using relative retention indices (standardised uptake value ratio [SUVr]) with respect to pontine, cerebellar and composite reference regions. Diagnostic and prognostic performance based on PET and CSF was evaluated using ROC analysis, multivariate linear regression and survival analysis with the Cox proportional hazards model.
Results: The cross-sectional study included 677 participants and revealed that pontine and composite SUVr values were better classifiers (AUC 0.88, diagnostic accuracy 85%) than CSF markers (AUC 0.83 and 0.85, accuracy 80% and 75%, for Aβ and tau, respectively). SUVr was a strong independent determinant of cognition in multivariate regression, whereas Aβ was not; tau was also a determinant, but to a lesser degree. Among the 396 patients from the longitudinal study, 82 (21%) converted to AD within 22 ± 13 months. Optimal SUVr thresholds to differentiate AD converters were quite similar to those of the cross-sectional study. Composite SUVr was the best AD classifier (AUC 0.86, sensitivity 88%, specificity 81%). In multivariate regression, baseline cognition (CDR and ADAS-cog) was the main predictor of subsequent cognitive decline. Pontine and composite SUVr were moderate but independent predictors of final status and CDR/ADAS-cog progression rate, whereas baseline CSF markers had a marginal influence. The adjusted HRs for AD conversion were 3.8 (p = 0.01) for PET profile, 1.2 (p = ns) for Aβ profile and 1.8 (p = 0.03) for tau profile.
Conclusions: Semi-quantitative amyloid PET appears more powerful than CSF markers for AD grading and MCI prognosis in terms of cognitive decline and AD conversion.
Keywords: ADNI; Alzheimer’s disease; Amyloid PET; CSF markers; MCI.
Figures
![Fig. 1](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/5405503/bin/13195_2017_260_Fig1_HTML.gif)
![Fig. 2](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/5405503/bin/13195_2017_260_Fig2_HTML.gif)
![Fig. 3](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/5405503/bin/13195_2017_260_Fig3_HTML.gif)
![Fig. 4](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/5405503/bin/13195_2017_260_Fig4_HTML.gif)
![Fig. 5](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/5405503/bin/13195_2017_260_Fig5_HTML.gif)
Similar articles
-
Comparison of Diagnostic Performances Between Cerebrospinal Fluid Biomarkers and Amyloid PET in a Clinical Setting.J Alzheimers Dis. 2020;74(2):473-490. doi: 10.3233/JAD-191109. J Alzheimers Dis. 2020. PMID: 32039853
-
Reciprocal Predictive Relationships between Amyloid and Tau Biomarkers in Alzheimer's Disease Progression: An Empirical Model.J Neurosci. 2019 Sep 11;39(37):7428-7437. doi: 10.1523/JNEUROSCI.1056-19.2019. Epub 2019 Jul 26. J Neurosci. 2019. PMID: 31350262 Free PMC article.
-
Amyloid-β assessed by florbetapir F 18 PET and 18-month cognitive decline: a multicenter study.Neurology. 2012 Oct 16;79(16):1636-44. doi: 10.1212/WNL.0b013e3182661f74. Epub 2012 Jul 11. Neurology. 2012. PMID: 22786606 Free PMC article.
-
CSF tau and the CSF tau/ABeta ratio for the diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).Cochrane Database Syst Rev. 2017 Mar 22;3(3):CD010803. doi: 10.1002/14651858.CD010803.pub2. Cochrane Database Syst Rev. 2017. PMID: 28328043 Free PMC article. Review.
-
Plasma and cerebrospinal fluid amyloid beta for the diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).Cochrane Database Syst Rev. 2014 Jun 10;2014(6):CD008782. doi: 10.1002/14651858.CD008782.pub4. Cochrane Database Syst Rev. 2014. PMID: 24913723 Free PMC article. Review.
Cited by
-
Diagnostic performance of molecular imaging methods in predicting the progression from mild cognitive impairment to dementia: an updated systematic review.Eur J Nucl Med Mol Imaging. 2024 Jun;51(7):1876-1890. doi: 10.1007/s00259-024-06631-y. Epub 2024 Feb 15. Eur J Nucl Med Mol Imaging. 2024. PMID: 38355740 Review.
-
A review of the flortaucipir literature for positron emission tomography imaging of tau neurofibrillary tangles.Brain Commun. 2023 Nov 16;6(1):fcad305. doi: 10.1093/braincomms/fcad305. eCollection 2024. Brain Commun. 2023. PMID: 38187878 Free PMC article. Review.
-
Prediction of Conversion from Mild Cognitive Impairment to Alzheimer's Disease Using Amyloid PET and Brain MR Imaging Data: A 48-Month Follow-Up Analysis of the Alzheimer's Disease Neuroimaging Initiative Cohort.Diagnostics (Basel). 2023 Nov 2;13(21):3375. doi: 10.3390/diagnostics13213375. Diagnostics (Basel). 2023. PMID: 37958271 Free PMC article.
-
Constructing a prognostic risk model for Alzheimer's disease based on ferroptosis.Front Aging Neurosci. 2023 Apr 27;15:1168840. doi: 10.3389/fnagi.2023.1168840. eCollection 2023. Front Aging Neurosci. 2023. PMID: 37181620 Free PMC article.
-
Amyloid-β PET in Alzheimer's disease: A systematic review and Bayesian meta-analysis.Brain Behav. 2023 Jan;13(1):e2850. doi: 10.1002/brb3.2850. Epub 2022 Dec 27. Brain Behav. 2023. PMID: 36573329 Free PMC article. Review.
References
-
- Ellendt S, Voß B, Kohn N, Wagels L, Goerlich K, Drexler E, et al. Predicting stability of mild cognitive impairment (MCI): findings of a community based sample. Curr Alzheimer Res. doi:10.2174/1567205014666161213120807. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous